Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Tayama Y et al. | [Influence of tacrolimus and ciprofloxacin on glucose metabolism]. | 2007 | Yakugaku Zasshi | pmid:17978565 |
Nagao K et al. | [Drug development from natural fermentation products: establishing a manufacturing process which maximizes the potential of microorganisms]. | 2010 | Yakugaku Zasshi | pmid:21048405 |
Fukudo M | [Individualized dosage regimen of immunosuppressive drugs based on pharmacokinetic and pharmacodynamic analysis]. | 2007 | Yakugaku Zasshi | pmid:17603267 |
Tanaka H et al. | [Discovery and development of a novel immunosuppressant, tacrolimus hydrate]. | 1997 | Yakugaku Zasshi | pmid:9306728 |
Muraki Y | [Factors affecting the pharmacokinetics after living donor liver transplant]. | 2012 | Yakugaku Zasshi | pmid:23023417 |
Iwamoto T et al. | [Successful treatment by tacrolimus in two patients with Osserman's grade III intractable myasthenia gravis and elderly IIb]. | 2004 | Yakugaku Zasshi | pmid:15067188 |
Niwa T et al. | Effect of cyclosporine and tacrolimus on cytochrome p450 activities in human liver microsomes. | 2007 | Yakugaku Zasshi | pmid:17202802 |
Shimizu K | Development of New Liposome Targeting Strategies for Application of Disease Therapies. | 2017 | Yakugaku Zasshi | pmid:28049894 |
Tanaka Y et al. | [Effect of tacrolimus on the pharmacokinetics and glucuronidation of SN-38, an active metabolite of irinotecan]. | 2013 | Yakugaku Zasshi | pmid:23328499 |
Li J et al. | [Regulatory effect of FK506 on the expression of CD152 and PD-1 in the liver allo-recipients]. | 2008 | Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi | pmid:18177621 |